-+ 0.00%
-+ 0.00%
-+ 0.00%
Asahi Kasei Therapeutics starts Japan Phase II trial of Cresemba in pediatric patients
Share
Listen to the news
Asahi Kasei Therapeutics starts Japan Phase II trial of Cresemba in pediatric patients
  • Asahi Kasei Therapeutics started a Phase II trial in Japan of isavuconazonium sulfate (Cresemba) for pediatric patients aged 1 to 17.
  • Study targets children at risk of deep mycoses, assessing safety profile, pharmacokinetics.
  • Cresemba remains unapproved for pediatric use in Japan despite pediatric clearances in several overseas markets.
  • Asahi Kasei Therapeutics holds Japan rights; adult Cresemba gained Japan clearance in December 2022, with a 40 mg capsule added in September 2024.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asahi Kasei Corporation published the original content used to generate this news brief on September 14, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending